Cargando…

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

Bisphosphonates are well established in the management of breast-cancer-induced bone disease. Recent studies have suggested that these compounds are effective in preventing the development of bone metastases. However, it is unclear whether this reflects an indirect effect via an inhibition of bone r...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagdev, S P, Coleman, R E, Shipman, C M, Rostami-H, A, Croucher, P I
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363858/
https://www.ncbi.nlm.nih.gov/pubmed/11308265
http://dx.doi.org/10.1054/bjoc.2001.1727
_version_ 1782153809356652544
author Jagdev, S P
Coleman, R E
Shipman, C M
Rostami-H, A
Croucher, P I
author_facet Jagdev, S P
Coleman, R E
Shipman, C M
Rostami-H, A
Croucher, P I
author_sort Jagdev, S P
collection PubMed
description Bisphosphonates are well established in the management of breast-cancer-induced bone disease. Recent studies have suggested that these compounds are effective in preventing the development of bone metastases. However, it is unclear whether this reflects an indirect effect via an inhibition of bone resorption or a direct anti-tumour effect. The breast cancer cell lines, MCF-7 and MDA-MB-231 cells were treated with increasing concentrations of the bisphosphonate, zoledronic acid, for varying time periods, in the presence or absence of paclitaxel. The effects of zoledronic acid were determined by assessing cell number and rate of apoptosis by evaluating changes in nuclear morphology and using a fluorescence nick translation assay. Zoledronic acid caused a dose- and time-dependent decrease in cell number (P< 0.001) and a concomitant increase in tumour cell apoptosis (P< 0.005). Short-term exposure to zoledronic acid was sufficient to cause a significant reduction in cell number and increase in apoptosis (P< 0.05). These effects could be prevented by incubation with geranyl geraniol, suggesting that zoledronic acid-induced apoptosis is mediated by inhibiting the mevalonate pathway. Treatment with zoledronic acid and clinically achievable concentrations of paclitaxel resulted in a 4–5-fold increase in tumour cell apoptosis (P< 0.02). Isobologram analysis revealed synergistic effects on tumour cell number and apoptosis when zoledronic acid and paclitaxel were combined. Short-term treatment with zoledronic acid, which closely resembles the clinical setting, has a clear anti-tumour effect on breast cancer cells. Importantly, the commonly used anti-neoplastic agent, paclitaxel, potentiates the anti-tumour effects of zoledronic acid. These data suggest that, in addition to inhibiting bone resorption, zoledronic acid has a direct anti-tumour activity on breast cancer cells in vitro. © 2001 Cancer Research Campaign http://www.bjcancer.com
format Text
id pubmed-2363858
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23638582009-09-10 The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel Jagdev, S P Coleman, R E Shipman, C M Rostami-H, A Croucher, P I Br J Cancer Regular Article Bisphosphonates are well established in the management of breast-cancer-induced bone disease. Recent studies have suggested that these compounds are effective in preventing the development of bone metastases. However, it is unclear whether this reflects an indirect effect via an inhibition of bone resorption or a direct anti-tumour effect. The breast cancer cell lines, MCF-7 and MDA-MB-231 cells were treated with increasing concentrations of the bisphosphonate, zoledronic acid, for varying time periods, in the presence or absence of paclitaxel. The effects of zoledronic acid were determined by assessing cell number and rate of apoptosis by evaluating changes in nuclear morphology and using a fluorescence nick translation assay. Zoledronic acid caused a dose- and time-dependent decrease in cell number (P< 0.001) and a concomitant increase in tumour cell apoptosis (P< 0.005). Short-term exposure to zoledronic acid was sufficient to cause a significant reduction in cell number and increase in apoptosis (P< 0.05). These effects could be prevented by incubation with geranyl geraniol, suggesting that zoledronic acid-induced apoptosis is mediated by inhibiting the mevalonate pathway. Treatment with zoledronic acid and clinically achievable concentrations of paclitaxel resulted in a 4–5-fold increase in tumour cell apoptosis (P< 0.02). Isobologram analysis revealed synergistic effects on tumour cell number and apoptosis when zoledronic acid and paclitaxel were combined. Short-term treatment with zoledronic acid, which closely resembles the clinical setting, has a clear anti-tumour effect on breast cancer cells. Importantly, the commonly used anti-neoplastic agent, paclitaxel, potentiates the anti-tumour effects of zoledronic acid. These data suggest that, in addition to inhibiting bone resorption, zoledronic acid has a direct anti-tumour activity on breast cancer cells in vitro. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-04 /pmc/articles/PMC2363858/ /pubmed/11308265 http://dx.doi.org/10.1054/bjoc.2001.1727 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Jagdev, S P
Coleman, R E
Shipman, C M
Rostami-H, A
Croucher, P I
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
title The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
title_full The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
title_fullStr The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
title_full_unstemmed The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
title_short The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
title_sort bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363858/
https://www.ncbi.nlm.nih.gov/pubmed/11308265
http://dx.doi.org/10.1054/bjoc.2001.1727
work_keys_str_mv AT jagdevsp thebisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel
AT colemanre thebisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel
AT shipmancm thebisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel
AT rostamiha thebisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel
AT croucherpi thebisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel
AT jagdevsp bisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel
AT colemanre bisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel
AT shipmancm bisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel
AT rostamiha bisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel
AT croucherpi bisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel